Histone Demethylase KDM5B as a Therapeutic Target for Cancer Therapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Histone Demethylase KDM5B as a Therapeutic Target for Cancer Therapy
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 8, Pages 2121
Publisher
MDPI AG
Online
2020-08-03
DOI
10.3390/cancers12082121
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B)
- (2020) Bing Zhao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Expression profile of H3K4 demethylases with their clinical and pathological correlation in patients with clear cell renal cell carcinoma
- (2020) Aman Kumar et al. GENE
- Recent Advances in the Chemical Synthesis and Evaluation of Anticancer Nucleoside Analogues
- (2020) Mieke Guinan et al. MOLECULES
- KDM5B promotes breast cancer cell proliferation and migration via AMPK-mediated lipid metabolism reprogramming
- (2019) Zhong-Guo Zhang et al. EXPERIMENTAL CELL RESEARCH
- Structure-based design and discovery of potent and selective KDM5 inhibitors
- (2018) Zhe Nie et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
- (2018) Katherine A. Hoadley et al. CELL
- KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance
- (2018) Wenxia Xu et al. International Journal of Biological Sciences
- Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1
- (2018) Yuhong Lu et al. MOLECULAR CANCER RESEARCH
- Overexpression of KDM5B/JARID1B is associated with poor prognosis in hepatocellular carcinoma
- (2018) Yoshinobu Shigekawa et al. Oncotarget
- Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor
- (2018) Kuang-Tai Kuo et al. Clinical Epigenetics
- KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance
- (2018) Kunihiko Hinohara et al. CANCER CELL
- Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target
- (2018) Yi-Chao Zheng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Identification of hub genes to regulate breast cancer metastasis to brain by bioinformatics analyses
- (2018) Dongyang Tang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Drug repurposing: progress, challenges and recommendations
- (2018) Sudeep Pushpakom et al. NATURE REVIEWS DRUG DISCOVERY
- HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive cases
- (2018) Gabriela Paroni et al. ONCOGENE
- Increased Expression of Lysine-Specific Demethylase 5B (KDM5B) Promotes Tumor Cell Growth in Hep3B Cells and is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma
- (2018) Jian Gong et al. MEDICAL SCIENCE MONITOR
- 2,4-Disubstituted quinazolines as amyloid- β aggregation inhibitors with dual cholinesterase inhibition and antioxidant properties: Development and structure-activity relationship (SAR) studies
- (2017) Tarek Mohamed et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- miR424-5p functions as an anti-oncogene in cervical cancer cell growth by targeting KDM5B via the Notch signaling pathway
- (2017) Yan Zhou et al. LIFE SCIENCES
- Drug repurposing in cancer
- (2017) Linda Sleire et al. PHARMACOLOGICAL RESEARCH
- Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448
- (2016) Oluwaseun Adebayo Bamodu et al. BMC CANCER
- Expression of Cancer Testis Antigens in Colorectal Cancer: New Prognostic and Therapeutic Implications
- (2016) Maciej Tarnowski et al. DISEASE MARKERS
- Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27
- (2016) Dong Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors
- (2016) Vassilios Bavetsias et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives
- (2016) Susan M. Westaway et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structural analysis of human KDM5B guides histone demethylase inhibitor development
- (2016) Catrine Johansson et al. Nature Chemical Biology
- An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells
- (2016) Maia Vinogradova et al. Nature Chemical Biology
- The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
- (2016) Bernard Pereira et al. Nature Communications
- KDM5 lysine demethylases are involved in maintenance of 3'UTR length
- (2016) L. P. Blair et al. Science Advances
- New carbocyclic N6-substituted adenine and pyrimidine nucleoside analogues with a bicyclo[2.2.1]heptane fragment as sugar moiety; synthesis, antiviral, anticancer activity and X-ray crystallography
- (2015) Constantin I. Tănase et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Silencing JARID1B suppresses oncogenicity, stemness and increases radiation sensitivity in human oral carcinoma
- (2015) Chun-Shu Lin et al. CANCER LETTERS
- Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
- (2015) Giovanni Ciriello et al. CELL
- Structural definitions of Jumonji family demethylase selectivity
- (2015) Ewa S. Pilka et al. DRUG DISCOVERY TODAY
- Immunohistochemical detection and clinicopathological significance of JARID1B/KDM5B and P16 expression in invasive ductal carcinoma of the breast
- (2015) L.H. Zhao et al. GENETICS AND MOLECULAR RESEARCH
- Transcriptional Regulation ofJARID1B/KDM5BHistone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia
- (2015) Haijun Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PLU-1/JARID1B overexpression predicts proliferation properties in head and neck squamous cell carcinoma
- (2015) ZHIBIN CUI et al. ONCOLOGY REPORTS
- Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer
- (2015) Lishuang Wang et al. TUMOR BIOLOGY
- JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression
- (2015) Xudong Shen et al. TUMOR BIOLOGY
- JARID1B promotes metastasis and epithelial-mesenchymal transition via PTEN/AKT signaling in hepatocellular carcinoma cells
- (2015) Bo Tang et al. Oncotarget
- SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination
- (2015) Wenfu Lu et al. Oncotarget
- MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators
- (2015) Emeli M. Nilsson et al. Oncotarget
- JARID1B Expression Plays a Critical Role in Chemoresistance and Stem Cell-Like Phenotype of Neuroblastoma Cells
- (2015) Yung-Ting Kuo et al. PLoS One
- JARID1B Is a Luminal Lineage-Driving Oncogene in Breast Cancer
- (2014) Shoji Yamamoto et al. CANCER CELL
- Inhibition of demethylases by GSK-J1/J4
- (2014) Bo Heinemann et al. NATURE
- Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells
- (2013) Alexander Roesch et al. CANCER CELL
- Connexin 26 is Down-Regulated by KDM5B in the Progression of Bladder Cancer
- (2013) Xin Li et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Depletion of JARID1B induces cellular senescence in human colorectal cancer
- (2013) KATSUYA OHTA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor
- (2012) Line H. Kristensen et al. FEBS Journal
- Histone Demethylase KDM5B Collaborates with TFAP2C and Myc To Repress the Cell Cycle Inhibitor p21cip (CDKN1A)
- (2012) P.-P. Wong et al. MOLECULAR AND CELLULAR BIOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Inhibition of Histone Lysine Methylation Enhances Cancer-Testis Antigen Expression in Lung Cancer Cells: Implications for Adoptive Immunotherapy of Cancer
- (2011) M. Rao et al. CANCER RESEARCH
- PLU-1/JARID1B/KDM5B is required for embryonic survival and contributes to cell proliferation in the mammary gland and in ER+ breast cancer cells
- (2011) Burchell INTERNATIONAL JOURNAL OF ONCOLOGY
- Jumonji/ARID1 B (JARID1B) Protein Promotes Breast Tumor Cell Cycle Progression through Epigenetic Repression of MicroRNA let-7e
- (2011) Doyel Mitra et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth
- (2010) Alexander Roesch et al. CELL
- Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway
- (2010) Shinya Hayami et al. Molecular Cancer
- Epigenetics in cancer
- (2009) S. Sharma et al. CARCINOGENESIS
- Epigenetics: Definition, Mechanisms and Clinical Perspective
- (2009) Cathérine Dupont et al. SEMINARS IN REPRODUCTIVE MEDICINE
- The emerging functions of histone demethylases
- (2008) Karl Agger et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation